Trials / Unknown
UnknownNCT04499313
Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19
The Outcome of Dexamethasone and Methylprednisolone Treatment for Patients With ARDS Caused by COVID-19
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Chattogram General Hospital · Other Government
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A randomized clinical trial designed and intended to evaluate the efficacy of Dexamethasone and Methylprednisolone as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by coronavirus disease 19 (COVID-19). Our aim is to find the best option for the treatment and management of ARDS in COVID-19 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexamethasone | Injectable solution |
| DRUG | Methylprednisolone | Injectable solution |
Timeline
- Start date
- 2020-08-02
- Primary completion
- 2020-11-15
- Completion
- 2020-11-30
- First posted
- 2020-08-05
- Last updated
- 2020-08-18
Locations
2 sites across 1 country: Bangladesh
Source: ClinicalTrials.gov record NCT04499313. Inclusion in this directory is not an endorsement.